Summary: Schoenfeld and colleagues report, in this issue, a measurable objective response rate in 6/28 (21.4%) of patients with advanced non–small cell lung cancer treated with lifileucel, a cell therapy product based on autologous tumor-infiltrating lymphocytes (TIL). Extending solid evidence in advanced melanoma that led to FDA approval of lifileucel, this new evidence bodes well for treating patients with other common tumor histologies, justifying important efforts by a large number of academic and biotechnology companies engaged in improving the TIL process. See related article by Schoenfeld et al., p. 1389 (1).

中文翻译：

---

肺癌过继细胞疗法：鼓舞人心的 TIL ACT 成为焦点


摘要：Schoenfeld 及其同事在本期报告中，使用 lifileucel（一种基于自体肿瘤浸润淋巴细胞的细胞治疗产品）治疗的晚期非小细胞肺癌患者中有 6/28 (21.4%) 取得了可测量的客观缓解率。直到）。这一新证据为晚期黑色素瘤提供了坚实的证据，导致 FDA 批准 lifileucel，这一新证据预示着治疗患有其他常见肿瘤组织学的患者，证明了大量学术和生物技术公司致力于改进 TIL 过程的重要努力。参见 Schoenfeld 等人的相关文章，第 17 页。 1389（1）。